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Abstract 
 
PAK4 is a Rho GTPase-regulated serine/threonine kinase that possesses critical functions in 
embryonic, neuronal and vascular development, immune defense and cancer. Constitutive 
PAK4 depletion causes embryonic lethality and mice with conditional PAK4 gene depletion 
in the heart and in the central nervous system displayed serious organ defects. PAK4 is 
overexpressed and genetically amplified in cancer cell lines as well as in cancer patients, 
including pancreas and breast. PAK4 also regulates many cellular functions related to cancer 
progression, including cell proliferation, survival and cell cycle as well as cell morphology, 
adhesion and migration, which are dependent on the actin cytoskeleton. Therefore, better 
understanding of the role of PAK4 in development, cancer progression and the mechanism 
behind that could help us to find suitable strategies to treat cancer.   
 
In paper I, we elucidated the role of PAK4 in pancreas development. PAK4 knockout mice 
were born at Mendelian ratios. Morphological and immunohistochemical examinations and 
quantifications indicated that exocrine, endocrine and ductal compartments retained the 
normal proportions and distributions upon PAK4 gene depletion. In addition, body weight 
records and a glucose tolerance test revealed no differences between wild type and PAK4 
knockout mice. Together, this suggests that PAK4 is dispensable for mouse pancreas 
development. This will facilitate future use of our Pdx1-Cre-driven conditional PAK4 knock 
out mouse model for testing in vivo potential functions of PAK4 in pancreatic disease models 
such as for pancreatitis and different pancreatic cancer forms. 
 
In paper II, we comprehensively characterized the human PAK4 interactome. We found that 
the PAK4 interactome was enriched in diverse protein networks, including the 14-3-3, 
proteasome, replication fork, CCT and Arp2/3 complexes. Moreover, we found that PAK4 
interacts with and phosphorylates VCA domain at Ser484/Ser485 and promotes Arp2/3- 
dependent actin polymerization in vitro. Also, PAK4 ablation in vivo reduced N-WASP 
Ser484/Ser485 phosphorylation and altered the cellular balance between G- and F-actin as 
well as the actin organization. By presenting the PAK4 interactome, we here provide a 
powerful resource for further investigations and we also indicate a novel mechanism by 
which PAK4 may regulate actin cytoskeleton remodeling. 
 
In paper III, we established PAK4 as a protumourigenic regulator of breast cancer acting 
through the non-canonical NF-κB subunit RelB. Our results demonstrated that PAK4 was 
overexpressed in human breast cancer and associated with poor prognosis. We found that 
PAK4 inhibition arrested cancer cell growth by inducing several senescence-like features. 
RNA sequencing and subsequent mechanistic exploration revealed that PAK4 inhibited NF-
κB signaling. Further, we identified RelB, a subunit of the non-canonical NF-κB family, as 
necessary for senescence-like growth arrest upon PAK4 depletion. Importantly, we 
pinpointed RelB as a direct substrate of PAK4 and mapped a PAK4 phosphorylation residue 
(S151) within the Rel-homology domain that directly influences RelB-DNA interactions and 
target gene expression.  
	
Taken together, these studies highlight the importance of PAK4 in cancer and provide new 
mechanisms and new views to understanding the role of PAK4 in cancer cell progression.   
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1 Introduction 
1.1 Cancer 
In human body, normal cells growth, division and death are tightly controlled by different 
gene and microenvironment. When our body’s control mechanism stops working or does not 
work properly, cancer will develop. Instead of death, cancer cells proliferate without control, 
forming more and more abnormal cells. Cancer is genetic disorder causing by sequential gene 
mutation accumulation1. Cancer is also a collection of diseases which can start almost 
anywhere in the human body, cancer cells divide without stopping and spread into 
surrounding tissues2. There are many possible causes inducing cancer, most common causes 
are smoking, radiation from sun or x-rays, alcohol, virus. Age and hereditary are also the very 
important cancer risk facts.  
As the second leading cause of death, cancer make about 0.6 million Americans death in 
20163. Lung, liver, colorectal, stomach, breast, pancreas cancer are the common causes of the 
cancer death globally.  
1.1.1 The hallmarks of cancer  
1.1.1.1 The hallmarks of cancer  
Different cancer may come from different parts of body, but they all share at least ten 
acquired distinctive and complementary capabilities4,5 (Figure 1). 1) Sustaining proliferation 
signaling. In normal tissues, growth signaling is carefully controlled to ensure the tissue have 
a normal architecture and function. To achieve rapid cell proliferation, cancer cells may carry 
somatic mutations to constitutively activate the cell replication or may disrupt normal 
negative-feedback loops. 2) Evading growth suppressors. Cancer cells often display 
mutations or malfunction of tumor suppressors (e.g. p53, pRB) to avoid limitation of cell 
growth and proliferation. 3) Resisting cell death. Tumor cells use different ways to limit 
apoptosis. Loss of p53 tumor suppressor function is the most common way by which cancer 
cells can get rid of this damage sensor. Except for that, tumors may increase the expression of 
anti-apoptotic regulators or by down regulating pro-apoptotic factors to achieve protection 
from apoptosis. 4) Enabling replication immortality. Cancer cells can bypass senescence and 
apoptosis, two natural barriers to proliferation, to exhibit unlimited replicative potential. 5) 
Inducing angiogenesis. Like normal cells, cancer cells need vasculature to supply nutrients as 
well as oxygen and to evacuate metabolic wastes. In most adult tissues, angiogenesis is 
quiescent, with the exception of a few physiologic processes like wound healing and female 
reproductive cycling. However, during cancer progression, angiogenesis is always turned on, 
causing quiescent vasculature to grow more vessels which help cancer cells growth. 6) 
Activating invasion and metastasis. From invasion to metastasis is a multistep process6, 
which begin from local invasion, then intravasate into surrounding blood vessels 
   2 
(intravasation), next, escape from the vessel lumina into the parenchyma of distant tissues 
(extravasation). Cancer cells can form small lesions (micrometastases) in distant tissues, and 
finally these small lesions can grow into big tumors (colonization). 7) Genome instability and 
mutation. Although the types of genome alteration are different in different cancer forms, 
large numbers of genome repair system defects, gene copy number and single-nucleotide 
polymorphism destabilizations are common in different kinds of cancer. 8) Tumor promoting 
inflammation. Inflammation does not just happen in the early stages of tumorgenesis, but also 
appear during the entire cancer progression. Inflammatory cells can release reactive oxygen 
species (ROS), which can cause mutations in the DNA of nearby cancer cells, thereby 
accelerating cancer towards states of malignancy. 9) Deregulating normal energy metabolism. 
In the aerobic environment, normal cells use glucose by glycolysis in the cytosol and then to 
carbon dioxide in the mitochondria; while in anaerobic conditions, cells prefer to use 
glycolysis alone. Warburg found that cancer cells, even under aerobic environment, could 
reprogram their glucose metabolism to use mainly glycolysis. 10) Avoiding immune 
destruction. To avoid the normal immune system to eliminate cancer cells, immunogenic 
cancer cells may disable some components of the immune system4,5. 
 
                
Figure 1. The hallmarks of cancer. This figure shows the ten hallmark features of the cancer as depicted by 
Douglas Hanahan and Robert A. Weinberg, Cell, 2011, 144, 5, 646–674. 
 
1.1.1.2 Cellular senescence 
More than 50 years ago, Leonard and Paul found that normal fibroblasts couldn’t grow 
indefinitely in culture, a phenomenon they called  “cellular senescence”. Now we know that 
lacking telomerase activity causes this phenomenon. What is cellular senescence? As showed 
in the Figure 2, senescence cells include multiple of the following features: 1) flattened and 
enlarged morphology; 2) lacking of proliferation; 3) expression of senescence associated β 
galactosidase activity (SA-β-gal); 4) expression of cell cycle inhibitors; 5) displaying of 
   3 
senescence associated secretory phenotype; 6) expression of genomic damage makers and 
displaying of senescence associated heterochromatin foci. However, no single feature is 
completely specific or universal for all the senescence types7.  
There are at least four different types of cellular senescence: DNA damage induced 
senescence, replicative senescence, stress induced senescence and oncogene induced 
senescence. DNA damage and telomere shortening can both trigger a DNA damage response, 
mediated by ATM, ATR and CHK1/2, leading to phosphorylation of p53 triggering down-
stream pathways. Many different types of stress can induce ROS, e.g. ROS is induced by the 
RAS-RAF-MEK-ERK pathway, which can active the p38 MAPK, leading to increase p53 
and p21. Oncogenes can also induce DNA damage response or ROS to further induce 
senescence7,8. Different stimulus can trigger senescence by different pathways, but many of 
them can activate p53, p15, p16, p21, and/or p27, inhibiting the CDK cyclin complexes and 
hypo-phosphorylated pRB, finally triggering proliferation arrest7.    
Senescence plays an important role in development, different diseases and during ageing, but 
here I will focus on senescence in cancer progression. Senescent cells are present in many 
premalignant lesions. In a KRAS G12V expressing mouse model, senescence is present at early 
stages of lung and pancreatic tumors9,10. BRAFV600E mutant also results in an increasing 
number of senescent cells in lung adenomas11,12. Inactivation of tumor suppressors, like 
PTEN, also can induce senescence in preneoplastic lesions13. However, senescence does not 
only occur in premalignant lesions, but also works as an effective barrier to tumor 
progression. For example, p53 loss accelerates the appearance of metastatic prostate cancer in 
PTEN-/- prostatic intraepithelial neoplasia lesions13. This example suggests that if mutations 
or other alterations cannot disable senescence to occur, oncogene induced senescence will 
block further growth and a tumor will not appear. Interestingly, chemotherapeutic drugs and 
ionizing radiation can induce senescence in cancer cells14. Taken together, pro-senescence 
therapies could be an effective way to treat cancer. Therefore, cellular senescence inducing 
drugs could be a useful approach for the development of novel cancer treatment.   
 
 
 
 
Figure 2.  Biomarkers of senescence cell.   
DDR: DNA damage response; SA-β-gal: 
senescence associated β galactosidase activity. 
(Based on Burton et al. Cell. Mol. Life Sci. (2014) 
71: 4373)  
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1.1.2 Breast and breast cancer  
1.1.2.1 Breast anatomy and physiology 
The breast in the adult woman is a milk-producing, tear-shaped gland. The structure of breast 
includes glandular, fatty and fibrous tissues, as well as nipple and areola. Glands are made up 
by 15-20 lobules and ducts, where the lobules produce milk and ducts carry the milk to the 
nipple15. Breast development starts from puberty and undergoes dramatic changes with the 
cycle of pregnancy/lactation/involution16. In the early pregnancy, the epithelial cells start 
extensive proliferation; and then in lactation period, epithelial cells differentiate to be 
specialized cells that express different milk components. When an infant is weaning, this 
process causes involution, in which most of the epithelial cells quickly die and the rest of the 
cells becomes a glandular structure that look like the pre-pregnant state16.  
1.1.2.2 Breast cancer Epidemiology 
Breast cancer is the most common cancer for women. Breast cancer causes the most women 
cancer deaths in the United States followed by lung cancer. Epidemiologic studies reveal a 
variety of risk factors for breast cancer. These risk factors include: Caucasian genetic origin; 
Country: development country; Age: younger age at parity and menarche, older age at first 
pregnancy or menopause; Family: breast cancer in the first-degree when young; Diet: red 
meat, animal fat and less consumption of fruits and vegetables; Hormone: hormone 
replacement therapy after menopause; alcohol consumption; exposure to ionizing radiation. 
Decreasing factors include: increasing physical activity and breast-feeding17-20.  
1.1.2.3 Breast cancer classification 
Breast cancers with different histopathological and biological features reveal different 
behaviors; therefore accurate grouping of breast cancers into clinically relevant subtypes is 
very importance for assessing prognosis and determining the appropriate therapy21,22. These 
clinical and pathological factors includes: patient age, histological features, tumor size, lymph 
node status and hormone receptor status23. Combining all these factors is more valuable than 
just viewing each one isolated.  
Gene expression profiling is used to classify breast cancer and to predict therapy response. 
Based on transcriptional expression patterns, breast cancer can be classified into five different 
groups21,22,24: Luminal A, Luminal B, Human epidermal growth factor receptor 2 (HER2) 
type, Basel-like and Normal-like. Luminal A and Luminal B are the estrogen receptors and/or 
progesterone receptors positive, and comprise about 75% of breast cancers. As the most 
common of breast cancer subtype, Luminal A represents 50%-60% of breast cancers. 
Luminal A cancers usually display high ER, low proliferation related genes, low histological 
grade, low mitotic activity, low degree of nuclear pleomorphism and carry relatively good 
prognosis. Luminal B comprises 15%-20% of breast cancers and is more aggressive than 
Luminal A. On average, Luminal B breast cancers have higher histological grade, higher 
proliferative index and a worse prognosis comparing to Luminal A. HER2-positive cancer 
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comprise about 15-20% of breast cancer. However, not all HER2-positive breast cancers 
belong to the HER2 molecular subtype.  The HER2 breast cancer type tends to display high 
tumor grade, lymph node-positive and a worse prognosis than the luminal subtypes. The 
Basal-like subtype accounts about 8%-37% of breast cancers. Most of Basal-like breast 
cancers overlap with the classification as triple negative breast cancers (estrogen receptors, 
progesterone receptors and HER2 are all negative).  The Basal-like subtype is characterized 
by high proliferation, high histological, nuclear grade and a poor prognosis21,22,24. Normal-
like subtype accounts for about 5%-10% of all breast cancer, triple negative, cytokeratin5/6 
and epidermal growth factor receptor negative, have good prognosis. There are a doubt about 
weather normal-like tumor is considered as a special subtypes or not22. 
1.1.2.4 Breast cancer treatment and challenges  
Over the past half-century, the five years survival rates of breast cancer patients have 
significantly increased thought combining the locoregional treatment and adjuvant systemic 
therapies. Locoregional therapy means local treatment of the cancer that does not affect the 
rest of the body; this includes surgery and radiation therapy. Surgery is usually the primary 
therapy for breast cancer. Systemic treatments means that the treatment can reach cancer cells 
anywhere in the body and is given in the forms of chemotherapy, hormone therapy, and/or 
targeted therapy. Chemotherapy can be given before surgery (neoadjuvant chemotherapy) 
and also after surgery (adjuvant chemotherapy). Estrogen receptors-positive and progesterone 
receptors-positive breast cancer can benefit from anti-hormone therapy, while HER2-positive 
breast cancer can benefit from treatments targeting HER2. Breast cancer treatment have been 
improved, but it still causes large numbers of lethality in cancer, so it is very important to find 
a new strategy to treat breast cancer25.  
 
1.1.3 Pancreas and pancreatic cancer  
1.1.3.1 Pancreatic anatomy and physiology 
Pancreas is a flat organ located deep in the human belly.  Pancreas is very interesting, because 
it intimately mixes two glands together into one organ26. One of these glands is called the 
exocrine pancreas, including mainly acinar and ductal cells. The exocrine acinar cells release 
enzymes into a series of ducts, finally entering the duodenum to help with food digestion. The 
exocrine components comprise more than 95% of the pancreatic mass. Another gland is 
called the endocrine pancreas. The endocrine pancreas also is called the islets of Langerhans, 
which is composed of small islands of cells. Islets comprise 1-2% of the pancreatic mass. The 
endocrine pancreas have five different cell types, α cell (glucagon), β cell (insulin), ε cell 
(ghrelin) δ cell (somatostatin) and PP cell (pancreatic polypeptides), which release different 
hormones into the bloodstream to help control blood glucose level (Figure 3).     
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Figure 3. Cell types and organization of pancreas. This illustration shows the major cell types and their 
arrangement in pancreas. Pancreas includes exocrine acini and islets of Langerhans. The acini are composed of 
exocrine acinar cells and ductal cell mainly. The islands of Langerhans contain α, β, δ, ε and PP (pancreatic 
polypeptide) cells, as well as blood cells. (Based on http://www.differencebetween.info/difference-between-
alpha-cell-and-beta-cell). 
1.1.3.2 Pancreatic cancer  
Pancreas cancer, especially pancreatic ductal adenocarcinoma (PDAC), which account for 
more than 95% of malignant tumors of the pancreas, carries a poor prognosis with a five-year 
survival of 3%–5% after discovery and a median survival of six months27-29. Today, some 
risk factors have been identified:  age, smoking, obesity and diabetes, consumption of red or 
processed meat and high-temperature cooking, a family history of pancreatic cancer and 
chronic pancreatitis all have an increased risk of developing pancreatic cancer27-29.  Targeted 
therapy has significant effect in the treatment for many cancers, including breast, melanoma, 
lung and colorectal cancer, but there is currently no targeted therapy with significant effect on 
pancreatic ductal adenocarcinoma. Pancreatic ductal adenocarcinoma remains a lethal disease 
and is estimated to be the second in the cancer related death by 203030,31. Gemcitabine is the 
current standard treatment27.  
 
1.2 p21-activated kinase 4 
1.2.1 Small GTPases  
Three decades ago, the Ras oncogene was the first small GTPase to be discovered, till today a 
large number of relative proteins forming the small GTPase superfamily have been 
discovered 32,33. Small GTPases are GDP-/GTP-regulated molecular switches. Generally, the 
GDP-binding form is inactive while the GTP-binding form is active33. Because GDP is 
tightly bound and GTP is hydrolyzed slowly, the regulating proteins guanine nucleotide 
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exchange factors (GEFs) accelerate GDP dissociation while GTPase activating proteins 
(GAPs) motivate GTP hydrolysis32 (Figure 4).   
According to sequence homologies and functional similarity, the small GTPases are divided 
into five subfamilies, the Ras, Rab, Arf, Ran and Rho subfamilies34. The Ras subfamily 
proteins play key roles in cell proliferation, differentiation, apoptosis, survival and gene 
expression32. The Rab subfamily proteins regulate membrane and protein trafficking in the 
secretory and endocytic pathways; the Arf subfamily proteins regulate endocytosis, 
exocytosis and vesicular trafficking; Ran regulates mitotic spindle organization and nucleus 
to cytoplasm transportation and the Rho subfamily proteins including Rac1, Rho and Cdc42 
are involved in regulation of cytoskeletal organization, cell polarity, cell cycle and gene 
expression32-35. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: The GTPase activity cycle between the inactive GDP-bound state and the active GTP-bound 
state. The inactive state is promoted by GTPase activating proteins (GAPs) stimulating GTP hydrolysis, the 
active state is promoted by guanine nucleotide exchange factors (GEFs) loading GTP and dissociating GDP. The 
actived GTPase interacts with downstream effectors that in turn activate downstream signaling pathways. (Based 
on Nielsen et al., Plant Physiology, Aug 2008, 147 (4) 1516-1526) 
 
1.2.2 The PAK family 
p21-activated kinases (PAKs) is the best characterized downstream effectors of Rho family 
small GTPases36,37. PAKs are serine/threonine protein kinases with six isoforms. According 
to sequence similarity, PAKs can be divided into two groups, group I (PAK1-3) and group II 
(PAK4-6). PAKs contain p21-binding domain (PBD) at the N-terminus and a kinase domain 
at the C-terminus. Group I and II PAKs have different structures, therefore regulate their 
activity in different manners38 (Figure 5). Group I PAKs form a dimer of two PAK 
molecules. The autoinhibitor domain (AID) partly overlaps with the PBD and binds to the 
kinase domain of another PAK molecule. When an activated small GTPase binds to PBD, 
this triggers AID disconnection from the kinase domain thereby releasing the kinase 
activity38,39. Group II PAKs is constitutively active and form monomers. Recent study shows 
they have autoinhibitory pseudosubstrate, which is similar to AID and adjacent to PBD. But 
the exact regulation is still unclear. There have two models available. Model 1: Activated 
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small GTPase bind to PAKs PBD, which lead to the kinase domain release. Model 2: 
Activated small GTPase bind to PAKs PBD, which trigers PAKs relocalization, and then the 
SH3 domain proteins bind to autoinhibitory pseudosubstrate, finally active the kinase 
activity36,38.  
As a downstream effector of Rho family small GTPases, the studies of PAKs initially focus 
on the cytoskeleton dynamics40. Later, PAKs have been shown to be involved in cancer 
progression, development of neuronal disease, viral pathogenesis, immunity and vascular 
disorders. Especially PAK1and PAK4 have been found overexpressed and amplified in many 
different cancer types, such as breast, pancreas, lung, ovary, prostate, gastric, leukemia, oral 
squamous-cell carcinoma and melanoma36,41.  
PAK regulates many cellular functions related to cancer progression, including cell 
proliferation, survival, cell morphology, adhesion and migration. 
                       
Figure 5: Domain structure of PAKs. All six PAKs have a serine/threonine kinase domain in the C-terminus 
and a PBD domain in the N-terminus. In all PAKs, an autoinhibition mechanism has been found. In group I 
PAKs, AID is overlap with PBD; In the Group II PAKs, an autoinhibitory psuedosubstrate was showed. The 
central region is more diverse. (Based on EYT al et., Journal of Molecular Signaling. 2014;9: 7. ) 
 
1.2.3 PAK4 function in cancer  
PAK4 has been shown overexpressed or genetically amplified in lots of cancer cell lines and 
cancer types including breast, pancreatic, prostate, liver, gastric, ovarian cancer and oral 
squamous cell carcinoma42-59. Overexpression of PAK4 correlates with tumor aggressiveness, 
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metastasis44,51,52 and poor prognosis42,48,51. Here I will focus on breast cancer and pancreas 
cancer. In MCF10A series of breast cell lines (MCF10A, MCF10AT, MCF10DCIS.com and 
MCF10CA1a), PAK4 expression is higher in more malignant MCF10CA1a60.  PAK4 
overexpression disrupts immortalized mouse mammary epithelial cells formed spherical acini 
with hollow lumen three dimensional architecture and normal apical/basolateral structures61. 
Another study shows that PAK4 is not just overexpressed in the breast cancer cell lines, but 
also overexpressed in breast cancer tumors, moreover, overexpression of PAK4 in NIH3T3 
cells leads to tumor formation in athymic mice, while PAK4 deletion inhibit tumorigenesis62. 
More importantly, high PAK4 expression correlate with larger tumor size, lymph node 
metastasis, poor overall and disease-free survival42. 
 
PAK4 is also overexpressed and amplified in pancreatic cell lines and a fraction of pancreatic 
PDAC cancer patients58,63,64.  Combining glaucarubinone and gemcitabine down-regulate 
active PAK4 in PANC-1 and MiaPaCa-2 cancer cell line, as well as in PANC-1 and 
MiaPaCa-2 xenograft, and then further reduce pancreatic cancer growth65. Knockdown of 
PAK4 restores sensitivity to gemcitabine in Capan-2, PANC-1, and SNU-410 pancreatic cell 
lines66. Data show PAK4 knockdown in a pancreas cancer cell line decrease cell cycle 
progression and apoptosis-resistance and also suppress growth and clonogenic ability63.  
1.2.4 PAK4 function in tissue development  
PAK4 is ubiquitously expressed; its expression is high in early mouse development and low 
when mice are adults67. PAK4 conventional knockout (KO) mice display lethality by 
embryonic day 11.5, links to defects in the nervous systems, vessels and the heart. PAK4 KO 
embryos have thin neuroepithelia in the hind and fore brain, and therefore defects in neuronal 
differentiation and axonal outgrowth. Moreover, PAK4 KO embryos show fetal blood vessels 
together with maternal blood vessels in order to get proper nutrient delivery; Further, PAK4 
KO embryos also display thin myocardial walls of the bulbous cortis and ventricle, which 
impairs ventricular function and cause its distended appearance67. 
Due to the early embryonic lethality of PAK4 KO mice, conditional PAK4 KO mice have 
been developed to study the role of PAK4 in different tissues. Epiblast-specific deletion of 
PAK4 mice still displays embryonic lethality and extraembryonic abnormalities68. Nervous 
system-specific deletion of PAK4 mice are born normal but exhibit growth retardation and 
die prematurely69. The secondary heart field conditional deletion of PAK4 shows 
abnormalities in the outflow tract and enlargement of the right ventricles and right atria70. 
However, the potential role of PAK4 in the pancreas has remained unknown. 
1.2.5 PAK4 signaling  
PAK4 is involved in cell cycle progression63,71-73. The expression level of PAK4 peaks in the 
early G1 phase and PAK4 knockdown decrease the amount of cells in the G1 phase and 
increase the amount of cell in the G2/M phase, which suggest that PAK4 plays an important 
role in cell cycle transition72. PAK4 may impact cell mitosis by two different aspects. Firstly, 
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PAK4 phosphorylate Ran on serine-135 and impedes its binding to RCC1 and RanGAP1 
during mitosis74. Secondly, PAK4 is important for spindle positioning during mitosis71,75.  
PAK4 also regulates cancer cell proliferation by regulating several key players in the cell 
cycle, such as CDC25A, cyclin D1, CDK6, P16, and Smad2/363,76-78. Further PAK4 may also 
regulate the PI3K /AKT pathway to achieve cell proliferation42,55,63. Taken together, all the 
evidences strongly suggest PAK4 significantly contribute to the cell proliferation.  
Resistance to apoptosis is an important sign of oncogenesis. PAK4 promotes cell survival not 
only by increasing cell proliferation, but also inhibits apoptosis. To this end, PAK4 
phosphorylates BAD, thereby blocking the interaction between BAD and BCL-XL and BCL-
2 to prevent apoptosis79. Further, in response to certain stimuli, PAK4 abolishes Caspase 8 
activation, thereby promoting resistance to apoptosis80.    
A role for PAK4 in transcription and translation has been indicated by several studies81-83. 
PAK4 associates with translational machinery components ribonucleoprotein complexes83 
and PAK4 also binds to the translation elongation factor Eef1a181 to regulate the HIF-1alpha 
translation in cancer cells82.   
1.2.6 PAK4 function in cytoskeleton dynamics and cell migration 
The actin cytoskeleton is a dynamic structure that plays critical roles in several different 
cellular processes, such as cell morphology, cell adhesion and migration84. Actin cytoskeleton 
dynamics in cells are regulated by a large number of actin binding proteins. For example, 
formins promote new unbranched actin filaments; The actin-related protein 2/3 complex 
(Arp2/3 complex) promote nucleation of new branching actin filaments; ADF/cofilin proteins 
enhance actin filament severing and depolymerization; and also profilin and VASP proteins 
regulate actin filament polymerization84.  
Regulation of cytoskeletal organization, cell morphology, adhesion and migration are 
relatively well-characterized functions of PAK4. PAK4 induces filopodia formation by 
interaction with activated Cdc42 in Golgi85. PAK4 also changes the cell morphology by 
interaction with and phosphorylation of GEF-H186. Moreover, PAK4 interacts with and 
phosphorylates LIMK1 and the slingshot homologue SSH-1, both part of a multi-protein 
complex with 14-3-3ζ, where PAK4 activates LIMK1, which in turn inactivates SSH1, 
leading to an increased ADF/cofilin activity that severs actin filaments and increases actin 
turnover57,87-91. PAK4 plays a key role in cell adhesion dynamics. Activated PAK4 expression 
induce focal adhesion disassembly either by phosphorylation of paxillin at Ser 27256, or via 
phosphorylation of integrin β5, moreover, PAK4 promote integrin ανβ5 mediated cell 
migration by increasing integrin ανβ5 turnover within adhesions thereby destabilizing focal 
adhesion92-94.  
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2 Aim of studies 
The general aim of this thesis is to investigate the function of PAK4 in cells; tissue 
development and cancer progression, to better understand the role of PAK4 in cancer. 
 
Special Aims: 
Paper I: To elucidate the role of PAK4 in pancreas development. 
Paper II: To investigate the PAK4 interactome and uncover new functions of PAK4.   
Paper III: To determine the role of PAK4 in cellular senescence and breast cancer 
progression. 
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3 Methodological considerations 
All the materials and methods used in this thesis are presented in detail in the papers, while 
general methodological considerations and limitations are discussed in this section.  
 
3.1 Cancer Cell lines 
Cancer cell lines derive from cancer patient are commonly used tools to study the biology of 
cancer and test the anti-cancer drugs, because they are cheap, infinite and easy to manipulate. 
However, cell cultures also have lots of limitations. 1) Lack of many tissue features: like 
blood vessels, oxygen pressure, hormone, original tissue structure and communication with 
different cell types. 2) Many number of passages may change characteristics, which no longer 
reflects the tumor from which it was derived95,96. 3) Different cell line cross-contamination95.  
Because normal cell culture has such limitations, we need better model to bridge the gap from 
bench to bedside. The three dimensional cancer cell cultures show better in studying dynamic 
interaction between cancer cells and surrounding extracellular matrix97. Ex vivo models, such 
as primary xenografts and orthotopic grafting, are more promising because these cancer cells 
have not adjusted to two dimensional tissue culture and are grown in a microenvironment that 
more closely mimics the context that they are derived from98,99. In vivo, cancer genetically 
engineered mouse models recapitulate many features of human cancer100. 
 
3.2 Genetically engineered mice 
Genetically engineered mice are the most commonly used mouse models to study tissue 
development and cancer progression. Transgenic, conventional and conditional gene knockin 
and KO are common strategies to generate genetically engineered mice. To get pancreas-
specific mouse models, cytokeratin 19, nestin, elastase, Mist1, p48 and Pdx1 have be used to 
limit the target gene expression to the pancreas101. In the paper I, we use the Pdx1 as the 
promoter to drive the Cre expression. Pdx1 starts to express from embryonic day 8.5, so it is a 
biomarker for pancreatic progenitor cells. Pdx1 expressed pancreatic progenitors later 
become adult ductal cells acinar and endocrine cells101. PAK4 protein expression level was 
below the detection limit in PAK4 KO mice using whole pancreas lysate shows Pdx1 
promoter is good choice for the whole pancreas KO. 
Genetically engineered mice have significantly contributed to our understanding of breast 
cancer initiation and progression. Breast cancer genetically engineered mice models are 
divided to different groups based on their features, including loss of tumor suppressor genes: 
p53, Brca1, Pten; or gain of an oncogene: Erbb2, Myc, H-ras and polyomavirus middle T 
(PyMT). To get mammary gland-specific mouse models, mammary tumor virus (MMTV), 
keratin-14 and whey acidic protein promoters have been utilized. In Paper III, we use MMTV 
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as a promoter, because most breast cancers originate from mammary gland epithelial cells 
and the MMTV promoter is mainly expressed in these epithelial cells. We employed an 
intensively studied breast cancer model driven by the MMTV-PyMT. We chose this model 
for two reasons: 1) This mouse model develops metastasis in lung and lymph nodes, while 
other transgenic models need to be combined to develop malignant cancers102. 2) This model 
shares many morphological and molecular features with human breast cancer. However, an 
obvious disadvantage of this mouse model is that PyMT itself is not expressed in human 
breast cancer103.  
 
3.3 Immunoprecipitation and mass spectrometry 
Most proteins cannot execute their functions alone, but need to interact with other proteins to 
form macromolecular complexes to fulfill their functions. Combining immunoprecipitation 
(IP) and mass spectrometry (MS) is a rapid, sensitive, and reliable technique to study protein-
protein interactions globally. There are three important steps for successfully identifying 
interactors using MS-based proteomics: 1) IP of the aim protein, 2) purification of the protein 
complex and 3) identification of the interacting proteins104.  For the first step, since we have 
not been able to find a suitable antibody against endogenous PAK4, we used the FLAG 
antibody conjugated agarose beads to IP FLAG tagged PAK4 from cells stably expressing 
FLAG-PAK4. For the second step, since agarose beads can bring down many unspecific 
proteins105, in order to get a purified protein complex, we used a FLAG peptide to elute the 
FLAG tag protein. For the third step, traditionally, after the purification of the protein 
complex, the sample will be injected to one dimension or two dimensions SDS-PAGE gel, 
finally compared the two lines or two gels to find the different bands or spots to identified 
using mass spectrometry104. However, recently developed isobaric tag for relative and 
absolute quantitation (iTRAQ)106 labeled mass spectrometry (8-plex iTRAQ) gave us the 
opportunity to quantitatively analyze our IP eluates. iTRAQ also facilitated the simultaneous 
analysis of four repeats (4 controls and 4 samples), allowing statistical analysis and increasing 
the confidence of our data (Paper II; Figure 1).  
Notably, proteins of the ribosome, spliceosome and ribonucleosome were enriched in the 
PAK4 interactome. These are potential candidates for false positive hits105, yet PAK4 was 
also shown to play a role in translation81,82,107. We therefore have chosen to report these as 
well as all other hits passing our set cutoff. 
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4 Results and discussion 
 
4.1 Paper I 
Pdx1-Cre-driven conditional gene depletion suggests PAK4 as dispensable for mouse 
pancreas development 
Conventional gene depletion of PAK1 or PAK3 caused functional deficits in the mouse 
pancreas108,109, while gene depletion of PAK5 or PAK6 did not110-113. The knowledge of the 
potential role of PAK4 in pancreas development is lacking, so here we explored 
aforementioned problem. This study suggests that, like PAK5 and PAK6, PAK4 is 
dispensable for mouse pancreas development. 
To generate conditional PAK4 KO mice targeting the pancreas, Pdx1-Cre mice and PAK4F/F 
mice were crossed68,114. Cre and PAK4 genotypes showed that mice with four different 
genotypes were born at the expected Mendelian ratio. Within the same genotypes, the 
numbers of male and female was approximately equal. The results suggest that deletion of 
PAK4 does not influence survival in any of the sexes.  
Next, Haematoxylin and Eosin stainings revealed, similar to wild type (WT), acinar structures 
of PAK4 KO pancreas were evenly distributed and acinar cell cytoplasm was equal in 
strength. No obvious difference in ductal structures and in islet between two cohorts was 
observed.  
To examine potential differences in islets between PAK4 KO and WT mice, area fraction 
covered by islets were measured and number of islets per pancreatic area were quantified, 
results displayed similarly for both genotypes.  
The proportion and localization of cell types are critical for the pancreas to conduct its 
functions115. Amylase staining showed similar expression level in acini throughout the entire 
pancreas; CK19 stained ductal structures revealed a branched ducts system in the whole 
pancreas; Insulin staining β-cells formed the majority of the islets, while glucagon staining α-
cells localized at the periphery of the islets with no differences between WT and PAK4 KO 
mice. Quantitative analyses of the islets also showed no significant differences were observed 
between WT and PAK4 KO mice.  
Glucagon and insulin are major hormones for body weight regulation116,117. We here tested 
whether conditional PAK4 gene depletion may affect the body weight at different ages. 
Analysis of both female and male mice at one, two, four and six months of age showed an 
expected increase in body weight with age, but with no discernible differences between the 
two genotypes. 
One of the important roles of the endocrine pancreas is maintenance of blood glucose 
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homeostasis118. To investigate whether loss of PAK4 may influence pancreatic function, we 
performed a glucose tolerance test and found WT and PAK4 KO mice displayed similar 
glucose induction and clearance curves, indicating that PAK4 gene depletion in the pancreas 
at two months does not affect the glucose regulatory function. Taken together, PAK4 is 
dispensable for mouse pancreas development.  
 
4.2 Paper II 
Identification of the PAK4 interactome reveals PAK4 phosphorylation of N-WASP and 
promotion of Arp2/3-dependent actin polymerization 
PAK4 regulates cell motility, F-actin remodeling, cell proliferation and apoptosis 
37,56,85,87,92,93,119-121, but the PAK4 interactome has not been systematically analyzed. In this 
paper, we comprehensively characterized the human PAK4 interactome by iTRAQ 
quantitative mass spectrometry of PAK4 - immunoprecipitations and found a new role for 
PAK4 in regulating the actin cytoskeleton. 
Combining cell fractionation and iTRAQ based MS; we characterized 313 proteins as PAK4 
interactors, 233 from whole cell lysates, 167 in the cytoplasmic fraction; and 54 in the nuclear 
fraction. By combined analysis of whole cell extracts and the two subcellular fractions 
(cytoplasmic and nuclear) enhanced the number of identified PAK4-associated proteins by an 
additional 80 hits. 
We validated the previously known PAK4 interactors 14-3-3 α/β and 14-3-3 ε122,123 and 
found a novel PAK4 interactor Arp2/3 complex subunit ARPC2. Then we identified actin 
cytoskeleton, 14-3-3, the replication fork and the proteasome these clusters enriched within 
the PAK4 interactome. Interestingly, the chaperonin containing TCP-1 complex (CCT 
complex) and the Arp2/3 complex, which previously not recognized to be associated with 
PAK4, were enriched in the actin cytoskeleton cluster. Further, we validate EGFP-PAK4 
could co-immunoprecipitate ARPC2 as well as CCTε and anti-CCTε also could co-
immunoprecipitate EGFP-PAK4.  
Because PAK1 phosphorylate ARPC1B124, we asked if PAK4 might also phosphorylate it. 
However, we did not detect any phosphorylation of the Arp2/3 complex subunits. 
Interestingly, we found that PAK4 phosphorylated the WASP VCA domain and 
Ser484/Ser485 in the VCA domain. 
Further, we examined the association within PAK4, the Arp2/3 complex and the VCA 
domain. We found that the interaction between PAK4 and the VCA domain is direct and the 
association detected by co-IP between PAK4 and the Arp2/3 complex might be indirect. We 
also found endogenous PAK4 co-immunoprecipitated endogenous N-WASP and endogenous 
N-WASP co-immunoprecipitated endogenous PAK4. Importantly, N-WASP and PAK4 co-
localized at F-actin bundles and leading edges at the cell periphery of MCF7 cells re-plated 
onto collagen type I.  
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Further study displayed that N-WASP Ser484/Ser485 phosphorylation decreased upon 
absence of PAK4 in H1299 cell. In vitro actin polymerization assay showed that pre-
incubation of the VCA domain with the PAK4 kinase domain increased actin polymerization 
and G- and F-actin fractionation experiment displayed that knockdown of PAK4 did not 
change the total amount of actin, the balance between G- and F-actin was shifted towards G-
actin. Finally, Immunofluorescence staining exhibited that PAK4 knock-down cells appeared 
more round with the phalloidin labeling enriched at the cell periphery, where the F-actin 
formed a cortical actin ring, while the control cells predominantly displayed an irregular 
shape and formed filopodia. Together, our results suggest that PAK4 dependent 
phosphorylation of N-WASP might promote actin polymerization, which is crucial for the 
cellular F-actin organization. 
 
4.3 Paper III 
PAK4 controls the non-canonical NF-κB component RelB to prevent senescence-like 
growth arrest in breast cancer 
PAK4 is frequently overexpressed in many human cancers and contributes to multiple 
hallmarks of cancer36. However, the functional role of PAK4 in tumourigenesis in vivo 
remains largely unknown and the signaling pathways controlled by PAK4 in cancer remain 
poorly understood. This study uncovers a vulnerability of cancer cells to PAK4 inhibition that 
may be explored as a therapeutic strategy. 
To examine expression levels of PAK4 and the potential prognostic ability for PAK4 in 
breast cancer patients in large cohort of breast cancer patients, we analyzed the METABRIC 
125 and The Cancer Genome Atlas126 data set and found that the level of PAK4 transcript was 
approximately two fold higher in breast tumors compared to their normal counterparts. We 
next asked weather PAK4 expression associated with the clinical outcome of breast cancer 
patients in the METABRIC cohort. The result showed that higher PAK4 expression was 
associated with worse disease specific survival	and increased rates of mortality.  
Using a genetic mouse model of PAK4 depletion to study tumourigenesis has not yet been 
employed, therefore we created conditional PAK4 gene depletion in PyMT transgenic breast 
cancer mouse model. We found elevated PAK4 protein levels in PyMT-driven mammary 
tumours. At 12 weeks of age, PyMT; PAK4 KO glands were less hyperplasic, exhibited 
fewer and smaller foci intermingled with normal ductal structures, and developed palpable 
tumours significantly later than PyMT; WT. Loss of PAK4 extended the median lifespan by 
35 days in female and 152 days in male. Taken together, these observations indicate that 
mammary epithelial disruption of PAK4 results in impaired PyMT-induced tumourigenesis 
and thus that PAK4 contributes to PyMT mammary tumourigenesis. 
The Gene Set Enrichment Analysis of RNA-Sequencing in Hs578T and BT549 revealed that 
senescence-associated gene signatures were overrepresented upon PAK4 depletion. Then we 
validate it in vitro, in vivo and ex vivo models. Upon siRNA-mediated PAK4 depletion, 
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Hs578T breast cancer cells adopted typical of a senescence response: flated and enlarged 
morphology, elevated enzymatic activity of SA-β-gal, decrease in BrdU-incorporation and 
upregulated the expression of genes involved in DNA damage/repair, cell cycle arrest and 
senescence associated secretory phenotype. We also examined the effect of PAK4 abrogation 
in a diverse collection of breast cancer cell lines, a primary cell line derived from a PyMT-
driven tumour, tumour cells derived from breast cancer patients as well as cancer cells more 
diverse histological origins. Remarkably, most of them displayed increased SA-b-gal activity. 
Taken together, these findings show that inhibition of PAK4 triggers a senescence-like 
response in cancer cells of various histological origins. 
We then expanded our analyses to additional in vivo models. We used two additional mouse 
models to test the relevance of PAK4 inhibition in vivo. Firstly, MCF-7 cells stably 
expressing shPAK4 or shControl were xenografted onto the back of nude mice. shPAK4 
tumours grew slower and were smaller at the experimental endpoint than the tumours in the 
shControl cohort. Importantly, the tumours expressing PAK4 shRNA exhibited several 
hallmarks of senescence including abundant SA-β-gal activity, decreased Ki67-positivity and 
accumulated p53. To further test the in vivo function of PAK4 we treated the PyMT mouse 
model with the PAK4 inhibitor PF-03758309. Tissues were stained with X-gal and analyses 
revealed that PF-03758309-treated tumours had a higher proportion of X-gal-covered areas 
compared to DMSO-treated samples. Taken together, these experiments extend our findings 
to in vivo settings. 
Further exploring our RNA-seq identified enrichment of NF-κB signatures upon PAK4 
knockdown. In addition, we found a signature of NF-κB signaling strongly anti-correlated 
with PAK4 expression in the METABRIC breast cancer patient dataset and RelB, one of NF-
κB subunit, had significant inverse association PAK4. Importantly, absence of RelB restored 
the proliferative capacity of Hs578T cells from the PAK4 knockdown-induced proliferation 
arrest showed that RelB is essential for growth arrest upon PAK4 depletion.  
Furthermore, we found PAK4 physiological interacted RelB and phosphorylated the Rel-
homology domain of RelB at serine 151 (S151). We also showed that the RelB S151E mutant 
had defective DNA binding and mimicking RelB-S151 phosphorylation decreased two major 
senescence regulators, Hes1 and CEBPB, mRNA expression. These results indicate that 
PAK4 is a RelB-kinase and that PAK4-dependent RelB phosphorylation on S151 is a novel 
regulatory mechanism that plays a critical role in the regulation of NF-κB signaling and 
senescence-associated factors. 
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5 Conclusions and future perspectives 
 
In paper I, the pancreas specific PAK4 depletion mice have been examined and there was no 
obviously difference in morphology and functions compared to the WT mice. This suggests 
that PAK4 is dispensable for mouse pancreas development. This will facilitate future use of 
Pdx1-Cre-driven conditional PAK4 KO mouse model for testing potential in vivo functions 
of PAK4 in pancreatic disease models such as for pancreatitis and different pancreatic cancer 
forms. Previous studies indicates that PAK4 is overexpressed and amplified in a fraction of 
pancreas adenomcarcinoma cell lines as well as in corresponding patient material. However, 
until now, there are no papers using a transgenic mouse model to study the function of PAK4 
in pancreas cancer progression. Crossing PAK4 KO model with pancreas cancer models, 
such as the KC model (Pdx1-Cre; LSL-Kras G12D/+) or KPC Model (Pdx1-Cre; LSL-Kras 
G12D/+; LSL-p53R172H/+) model, will possibly elucidate the role of PAK4 in pancreas cancer 
progression. 
 
In paper II, we comprehensively characterized the human PAK4 interactome, which provides 
a valuable resource for future investigations on the role of PAK4 in physiology and disease. 
The PAK4 interactome provides a substantial number of new leads for future studies of the 
roles and molecular functions of PAK4. In this study, we found several key proteins of the 
DNA replication fork in the PAK4 interactome, suggesting that PAK4 may regulate the DNA 
replication fork, adding complexity to the role of PAK4 in cell proliferation. Another 
potential function of PAK4 interacting proteins is to control PAK4 activity and stability. The 
ubiquitin-proteasome system and the lysosomes are common ways to degrade proteins. We 
found a large number of proteasome subunits in the PAK4 interactome, which is consistent 
with the recent report that PAK4 can be ubiquitinated and degraded by the proteasome. 
 
We found that PAK4 regulates the actin organization by interacting with and phosphorylating 
N-WASP at Ser484/Ser485. We thereby propose a new mechanism for PAK4 regulation of 
actin cytoskeleton dynamics. However, at this stage, it remains elusive how PAK4 may help 
balance the interplay between actin polymerization and depolymerization at the cell leading 
edge to achieve rapid cell migration, which will require further investigations. In addition, we 
report a novel interaction between PAK4 and the CCT complex, a chaperonin that is essential 
for folding of the cytoskeletal proteins actin and tubulin and. Several CCT subunits have also 
been shown to regulate the actin cytoskeleton and the formation of cell surface protrusions. 
However, whether the CCT complex is a PAK4 substrate and if their association may be 
involved in regulation of the actin cytoskeleton remains to be examined. 
 
In paper III, we establish PAK4 as a protumourigenic regulator of breast cancer acting 
through the non-canonical NF-κB subunit RelB. Our study thus uncovers a vulnerability of 
cancer cells to PAK4 inhibition that may be explored as a therapeutic strategy.
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